This prospective cohort study was conducted within the Integrated Prevention of MTCT (IPMTCT) program, a national system of HIV, syphilis and hepatitis B testing, treatment and surveillance that includes all pregnant women in China. This system covers all medical institutions, and all pregnant women are offered free opt-out HIV testing during their first prenatal visit in Guangzhou. If a patient is diagnosed with HIV, more detailed information is retrieved from the system and double-checked. Pregnant women living with HIV are offered free ART and follow-up care until delivery.
Infants born to HIV-infected mothers are subjected to high-risk neonatal management and are followed by pediatricians at 1, 3, 6, 9, 12, and 18 months of age. These infants are provided with free antiretroviral prophylaxis, HIV testing during early infancy, HIV-antibody testing and physical examinations involving standard procedures to establish the infection status. Infants undergo early-infant HIV testing and a physical examination by pediatricians at 1 and 3 months of age, respectively.
The present study included all HIV-infected pregnant women reported to the IPMTCT system in Guangzhou between October 2009 and May 2018. HIV-infected pregnant women who elected to terminate their pregnancy were excluded. Any adverse pregnancy outcomes of women with singleton pregnancy were analyzed.
The study was conducted in accordance with the China IPMTCT guidelines. All study protocols were approved by the Center for National Women’s and Children’s Health, China CDC. Informed consent was obtained from all participating mothers.
The treatment regimen for the prevention of MTCT of HIV in Guangzhou was updated three times. By 2015, all HIV-positive pregnant women began receiving zidovudine-based cART (zidovudine, lamivudine and lopinavir/ritonavir) or efavirenz- based cART (tenofovir, lamivudine and efavirenz). Before 2015, two regimens were provided: a preventive antiviral regimen and a therapeutic antiviral regimen according to the maternal condition. The specific medication plans are listed in Table 1. After ART initiation, clinical follow-ups were conducted through an integrated primary care service that provided antenatal and HIV care.
Year Prophylaxis regimen Treatment regimen Regimen / medication period Regimen Eligibility Regimen Eligibility From Feb. 2011, to Aug. 2011 Recommended regimen From gestational week 28 to labor: AZT 300 mg bid At labor: immediately AZT 300 mg + NVP 200 mg + 3TC 150 mg oral, and then AZT 300 mg every 3 hours, 3TC 150 mg every 12 hours Postpartum: AZT 300 mg bid + 3TC 150 mg bid for 1 week No indication for ART, and did not receive ART previously AZT + 3TC +
Viral load > 1,000 copies/mL Minimum-level plan NVP 200 mg post-labor, once From Sep. 2011 to June 2015 Pregnancy (≥ 14 w) and labor AZT 300 mg + 3TC 150 mg + LPV/r 400/100 mg, bid or AZT 300 mg + 3TC 150 mg, bid, +EFV 600 mg, qd CD4 cell count
> 350 cells/mL and/or WHO stage I/II disease
AZT 300 mg + 3TC 150 mg, bid, + EFV 600 mg, qd, as early as possible CD4 cell count ≤ 350 cells/mL and/or WHO stage III/IV disease Postpartum 1. Artificial feeding, stop ART after delivery 2. Breastfeeding, continue ART till 1 week after stopping breastfeeding Labor A single dose of NVP 200 mg, and AZT 300 mg + 3TC 150 mg, bid, until the end of delivery Pregnant women with confirmed HIV infection during labor who fed their babies artificially AZT 300 mg + 3TC 150 mg + NVP 200 mg, bid, as early as possible CD4 cell count < 250 cells/mL and/or WHO stage III/IV disease Postpartum AZT 300 mg + 3TC 150 mg, bid, for 7 days Option 1 AZT + 3TC + LPV/r or AZT + 3TC + EFV (usage and dosage as listed above), 1 week after breastfeeding cessation Pregnant women with confirmed with HIV infection during labor who breastfed their babies Option 2 A single dose of NVP 200 mg, and AZT 300 mg + 3TC 150 mg, bid, until the end of delivery; Continued AZT 300 mg + 3TC 150 mg, bid, post-labor for 7 days. After July 2015 AZT 300 mg bid + 3TC 300 mg qd + LPV/r 400/1,000 mg bid Pregnant women who did not receive ART during pregnancy or labor, regardless of CD4 level and stage; start ART immediately. TDF 300 mg qd + 3TC 300 mg qd + EFV 600 mg qd 1. If virus suppression is ideal, retain the original regimen. 2. If virus suppression is not ideal, adjust the ART regimen. Pregnant women who have received ART before pregnancy; evaluate effect based on the viral load. Note. ART, antiretroviral therapy; AZT, Zidovudine; NVP, evirapine; 3TC, Lamivudine; EFV, efavirenz; LPV/r, Lopinavir/ritonavir; TDF, Tenofovir; qd, once-daily; bid, twice-daily.
Table 1. Description of the three maternal medication plans
All HIV-exposed infants were prescribed once-daily nevirapine or twice-daily zidovudine within 6-12 hours after birth, which continued for 4-12 weeks depending on the MTCT risk assessment. All infants included in this study were fed artificially.
The study participants were categorized into three groups based on the medication regimens used by the pregnant women: (1) cART, a combination of three or more antiretroviral drugs; (2) ART comprising one or two antiviral drugs, referred to as ‘mono/dual ART’ or (3) no treatment.
The outcomes of interest were the composite adverse pregnancy outcomes, including at least one of the following: (1) preterm birth, defined as a live birth before a gestational age of 37 weeks; (2) small for gestational age (SGA), defined as a live infant birthweight of less than the 10th percentile by gestational age and sex (based on the Intergrowth-21st Project Standards); (3) congenital anomaly detected by the nurse midwife during neonatal examination or structural screening via B-ultrasound; (4) stillbirth, defined as fetal death occurring before/during labor (based on a 1-min Apgar score of 0); (5) spontaneous abortion, defined as a spontaneous pregnancy loss at or before 20 weeks of gestation and (6) ectopic pregnancy.
The following main outcomes were used to evaluate the adverse effects of in utero HIV and ART exposure on early infants: (1) infant mortality, defined as the death of live-born infant within 1 year old. (2) MTCT of HIV: as per the China IPMTCT guideline, HIV-exposed infants are diagnosed via virological testing at 4 and 12 weeks of age. A positive virological test indicates that the infant is HIV-infected, whereas a negative test indicates the need for repeated serological HIV antibody testing at 12 and 18 months of age. If both subsequent HIV antibody tests are positive, the child is considered HIV-infected. (3) Stunting, defined as a length-for-age Z score (LAZ) by sex of less than -2. (4) Underweight, defined as a weight-for-age Z score (WAZ) by sex of less than -2. (5) Wasting, defined as a weight-for-length Z score (WLZ) by sex of less than -2. We calculated the infant LAZ, WAZ, and WLZ based on Fenton and WHO growth reference standards, using a corrected age for infants born prior to 37 completed weeks of gestation.
The socio-demographic and clinical characteristics of HIV-positive mothers, including age, parity, educational level, occupation, marital status, household registration, maternal CD4 count and HIV viral load during the third trimester, mode of delivery and ART regimens, were collected. Information about their infants, including birthdate, gestational age, sex, birthweight, birthlength, birth defects, neonatal diseases, antiretroviral prophylaxis, early infant diagnosis and HIV antibody testing, weights and heights at all follow-up time-points were recorded using a national standardized format with assistance from medical professionals. All maternal CD4 counts and HIV viral loads during the third trimester were tested at Guangzhou No. 8 People’s Hospital, a single specialized infectious disease hospital in Guangdong Province.
The accuracy of all case cards was evaluated. The gestational age at birth was expressed as completed weeks and based on the first- or second-trimester ultrasound test. In the absence of a recorded ultrasound result, the last menstrual period was used to calculate gestational age. The infant birthlength and birthweight were abstracted from clinical records. Trained nurses used a firm recumbent stadiometer to measure infant lengths to the nearest 0.1 cm and weights to the nearest 10 grams at all subsequent study visits.
A descriptive analysis was used to describe the socio-demographic information of the study participants. The chi-square test was used to describe and compare categorical socio-demographic data and clinical characteristics between different groups of participants receiving different treatment regimens. The t-test, analysis of variance and non-parametric test were used to compare continuous data and characteristics among different groups according to the results of normal distribution tests. The risks of adverse pregnancy outcomes and early infant growth outcomes associated with the treatment regimens were estimated using a logistic regression adjusted for the mother’s education level (primary or no education, junior high school, senior high school and higher, missing or unknown), ethnicity (Han, Others), parity (primiparous, parous), residence registration (Guangdong Province, other province/country), gestational age (weeks) at the first antenatal care visit and number of antenatal care visits. The mode of delivery (spontaneous labor, elective caesarean section, emergency caesarean section), gestational age at delivery (days), birthweight (grams) and infant antiretroviral prophylaxis (nevirapine, zidovudine, unmedicated) were also included as covariates when analyzing the risks of early infant growth outcomes. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA) and the Statistical Package for Social Sciences version 20 software package for Windows (SPSS Inc, Chicago, IL, USA). All reported P
values are based on a two-sided test with a significance level of α = 0.05.
From October 2009 to May 2018, 802 pregnant women with HIV were recruited in this study. Of these women, 361 received cART during pregnancy, 91 received mono/dual ART and 133 did not receive ART. Of the 562 total live births, 6 infants were infected with HIV via MTCT (Figure 1).
No significant differences in the maternal age, marital status and newborn’s sex were observed between the treatment regimens (Table 2). However, pregnant women who had not received ART were more likely to exhibit the following characteristics: non-Han ethnicity, lower education level, residence in another province/country, multiparous, first antenatal care at a later date, less antenatal care, a lower CD4 count during pregnancy, lower rate of selective cesarean section, later delivery, heavier birthweight of her baby and reduced likelihood of infant antiretroviral prophylaxis. HIV pregnant women receiving cART and those with mono/dual drug therapy began ART at similar gestational ages and had similar durations of ART during pregnancy.
Characteristics cART (N = 361) Mono/dual ART (N = 91) No treatmen (N = 133) P-value Mother’s age in years (mean ± SD) 29.8 ± 5.0 29.0 ± 5.1 28.6 ± 6.0 0.07 Ethnicity, n (%) < 0.01 Han 329 (91.1) 84 (92.3) 103 (77.4) Others 32 (8.9) 7 (7.7) 30 (22.6) Mother’s education, n (%) < 0.01 Primary or no education 36 (10.0) 14 (15.4) 27 (20.3) Junior high school 179 (49.6) 42 (46.2) 57 (42.9) High school and higher 121 (33.5) 26 (28.6) 30 (22.6) Missing or unknown 25 (6.9) 9 (9.9) 19 (14.3) Mother’s occupation, n (%) 0.03 Housewife or none 190 (52.6) 48 (52.7) 66 (49.6) Physical work 106 (29.4) 33 (36.3) 36 (27.1) Office work 20 (5.5) 6 (6.6) 4 (3.0) Missing or unknown 45 (12.5) 4 (4.4) 27 (20.3) Marital status, n (%) 0.10 Single 57 (15.8) 15 (16.5) 32 (24.1) Married 304 (84.2) 76 (83.5) 101 (75.9) Household registration, n (%) 0.02 Guangdong Province 191 (52.9) 44 (48.4) 52 (39.1) Other province/country 170 (47.1) 47 (51.6) 81 (60.9) Parity, n (%) < 0.01 Primiparous 283 (78.4) 74 (81.3) 84 (63.2) Parous 78 (21.6) 17 (18.7) 49 (36.8) Gestational week at the first antenatal care in weeks
(mean ± SD)
19.0 ± 9.1 21.3 ± 10.2 26.6 ± 12.8 < 0.01* Gestational age starting ART in weeks (mean ± SD) 20.7 ± 9.7 21.6 ± 10.9 − 0.45 Duration of ART during pregnancy in weeks (mean ± SD) 16.7 ± 9.9 15.9 ± 10.4 − 0.48 Number of antenatal care visits (mean ± SD) 4.7 ± 2.7 3.8 ± 3.0 0.5 ± 1.2 < 0.01* Last CD4 count (cells/μL) during pregnancy, n (%) < 0.01 < 350 84 (23.3) 19 (20.9) 11 (8.3) ≥ 350 135 (37.4) 30 (33.0) 5 (3.8) Missing or unknown 142 (39.3) 42 (46.2) 117 (88.0) Mode of delivery, n (%) < 0.01 Spontaneous labor 39 (10.8) 11 (12.1) 63 (56.8) Elective Caesarean section 265 (73.6) 64 (70.3) 13 (11.7) Emergency Caesarean section 56 (15.6) 16 (17.6) 35 (31.5) Gestational age at delivery in days (mean ± SD) 265.3 ± 10.4 265.3 ± 14.0 269.2 ± 20.8 < 0.01* Birth weight in grams (mean ± SD) 2777.3 ± 449.0 2737.4 ± 432.5 3027.2 ± 521.6 < 0.01 Newborn’s sex, n (%) 0.29 Male 83 (56.1) 41 (45.6) 54 (51.4) Female 65 (43.9) 49 (54.4) 51 (48.6) Infant antiretroviral prophylaxis, n (%) < 0.01 Nevirapine 113 (76.9) 62 (68.9) 18 (17.1) Zidovudine 33 (22.4) 21 (23.3) 26 (24.8) Unmedicated 1 (0.7) 7 (7.8) 61 (58.1) Note. Mean ± SD = mean ± standard deviation; *Non-parametric test was used.
Table 2. Maternal, pregnancy and delivery characteristics stratified by antiretroviral regimen during pregnancy
Overall, 202 (35.1%) of all HIV-infected women experienced an adverse pregnancy outcome, and 121 (31.3%) of all infants included in this analysis exhibited adverse effects on early growth at 4 weeks of age. The rates of adverse pregnancy outcomes, spontaneous abortion, ectopic pregnancy, stillbirth, infant death and perinatal HIV infection were higher among women not receiving ART, compared to those receiving cART or mono/dual ART (P < 0.05). However, the rate of SGA was higher among women receiving cART, compared to those not receiving treatment (P < 0.05) (Table 3). Meanwhile, no significant differences in congenital anomalies, preterm birth, adverse early growth, stunting, underweight and wasting at 1 month of age were observed among the three treatment groups.
Outcomes cART (n = 361) Mono/dual AR (n = 91) No treatment (n = 133) P-value Adverse pregnancy outcomes, n (%) 112 (31.9) 31 (34.1) 59 (44.4) 0.04 Spontaneous abortion 0 0 6 (4.5) − Ectopic pregnancy 1 (0.3) 0 14 (10.5) − Stillbirth 3 (0.9) 1 (1.1) 8 (7.1) < 0.01 Congenital anomaly 2 (0.6) 2 (2.2) 2 (1.8) 0.33 Preterm birth 44 (12.5) 15 (16.5) 23 (20.5) 0.33 SGA 77 (21.9) 17 (18.7) 14 (10.5) 0.02 Adverse early growth outcomes, n (%) 87 (32.7) 17 (25.0) 17 (32.1) 0.47 Infant death 1 (0.3) 0 3 (2.7) < 0.01 HIV infection via MTCT 1 (0.3) 0 5 (4.4) − Stunting 41 (15.4) 12 (17.1) 2 (3.9) 0.07 Underweight 34 (12.7) 6 (8.6) 5 (9.8) 0.57 Wasting 35 (13.1) 4 (5.7) 6 (11.8) 0.23 Note. SGA, small for gestational age; MTCT, mother-to-child transmission.
Table 3. Comparison of adverse pregnancy outcomes and adverse early growth effects stratified by antiretroviral regimen during pregnancy
The relationships among ART initiation timing of HIV-infected pregnant women and adverse outcomes suggested that 1-month-old infants of participants who started ART in the second or third trimester were more likely to be wasting than those of participants starting ART in the first trimester or delivery/postpartum (P < 0.05) (Table 4). No significant differences were observed in adverse pregnancy outcomes, infant death, HIV infection via MTCT, stunting and underweight at 1 month of age among the four groups of ART initiating timings.
Outcomes 1st Trimester
(n = 89)
(n = 247)
(n = 84)
(n = 39)
P-value Adverse pregnancy outcomes, n (%) 37 (41.6) 86 (34.8) 26 (31.0) 12 (30.8) 0.46 Ectopic pregnancy 1 (1.1) 0 0 0 0.28 Stillbirth 0 1 (0.4) 0 3 (7.7) 0.24 Congenital anomaly 1 (1.1) 2 (0.8) 0 1 (2.6) 0.47 Preterm birth 12 (13.6) 45 (18.2) 8 (9.5) 6 (16.2) 0.27 SGA 26 (29.5) 52 (21.1) 20 (23.8) 5 (13.5) 0.21 Adverse early growth outcomes, n (%) 17 (23.3) 67 (36.6) 16 (28.6) 3 (14.3) 0.05 Infant death 0 0 0 1 (2.6) 0.28 HIV infection via MTCT 0 0 0 1 (2.6) 0.28 Stunting 13 (17.8) 32 (17.1) 7 (12.5) 1 (5.0) 0.49 Underweight 10 (13.7) 22 (11.8) 7 (12.5) 1 (5.0) 0.82 Wasting 2 (2.7) 29 (15.5) 8 (14.3) 0 0.01 Note. SGA, small for gestational age; MTCT, mother-to-child transmission.
Table 4. Comparison of adverse pregnancy outcomes and adverse early growth effects stratified byART initiation timing
In the unadjusted analyses and model 1, women who received cART had a significantly lower risk of any adverse pregnancy outcome [odds ratio (OR) = 0.59, 95% confidence interval (CI): 0.39-0.89; adjusted OR (aOR) = 0.53, 95% CI: 0.35-0.81] and higher risk of SGA (OR = 1.92, 95% CI: 1.04-3.56; aOR = 1.87, 95% CI: 1.00-3.51), compared to women not receiving treatment. After adjustment for pregnancy covariates, however, no differences in any adverse pregnancy outcomes or SGA were observed among women receiving different antiviral regimens Table 5). Neither the unadjusted nor adjusted analyses indicated differences in any adverse early growth outcomes of 4-week-old infants born to women receiving different antiviral regimens.
Items cART Mono/dual ART No treatment Any adverse pregnancy outcome Number of women, n (%) 112/351 (31.9%) 31/91 (34.1%) 59/133 (44.4%) Crude Model, OR (95% CI) 0.59 (0.39, 0.89) 0.65 (0.37, 1.13) 1 (ref) Model 1a, OR (95% CI) 0.53 (0.35, 0.81) 0.60 (0.34, 1.05) 1 (ref) Model 2b, OR (95% CI) 1.16 (0.64, 2.08) 1.28 (0.65, 2.51) 1 (ref) SGA Number of women, n (%) 77/351 (21.9) 17/91 (18.7) 14/133 (10.5) Crude Model, OR (95% CI) 1.92 (1.04, 3.56) 1.51 (0.70, 3.27) 1 (ref) Model 1a, OR (95% CI) 1.87 (1.00, 3.51) 1.47 (0.67, 3.22) 1 (ref) Model 2b, OR (95% CI) 2.10 (0.99, 4.44) 1.53 (0.64, 3.66) 1 (ref) Any adverse early growth Number of children, n (%) 87/266 (32.7%) 17/68 (25.0%) 17/53 (32.1%) Crude Model, OR (95% CI) 1.03 (0.55, 1.94) 0.71 (0.32, 1.57) 1 (ref) Model 1a, OR (95% CI) 1.07 (0.56, 2.03) 0.75 (0.33, 1.69) 1 (ref) Model 2b, OR (95% CI) 1.18 (0.55, 2.57) 0.81 (0.33, 2.00) 1 (ref) Model 3c, OR (95% CI) 1.10 (0.39, 3.11) 0.71 (0.23, 2.23) 1 (ref) Note. SGA, small for gestational age. aModel 1: covariates mother’s education, ethnicity, household registration, parity; bModel 2: covariates in model 1, and gestational week at the first antenatal care, number of antenatal care; cModel 3: covariates in model 2, and Mode of delivery, gestational age at delivery, birthweight and infant antiretroviral prophylaxis.
Table 5. Adverse pregnancy outcomes and adverse early infant growth effects at 4 weeks of age stratified by antiretroviral regimens during pregnancy
This study contributes to the limited body of evidence regarding the effects of ART regimens on mother-infant pairs in China and the safety and effectiveness of ART regimens during pregnancy. Our findings suggest that the rates of spontaneous abortion, ectopic pregnancy, stillbirth, infant death and HIV infection of infants via MTCT were higher among women who did not receive ART, suggesting that a failure to provide ART to HIV-infected pregnant women may have more serious consequences. In addition, although we observed no significant effect of the treatment regimen type on adverse early infant growth, the rate of SGA was higher among women receiving cART, compared with other regimens.
The correlation between preterm birth and ART is often debated. Our study found a low rate of prematurity and no statistically significant relationship between preterm birth and the use of different ART regimens, consistent with previously published findings[29-31]. Although recent studies suggested that a protease inhibitor (PI)-based ART regimen may increase the risk of preterm birth[17,32], our further analysis did not confirm this association (The rates of preterm birth were 15.4%, 15.5%, 16.7%, and 16.2% for HIV-infected women receiving NNRTI-based cART, receiving PI-based cART, receiving mono/dual ART and receiving no treatment, respectively. Data was shown in Table 6. Some studies demonstrated fetal exposure to antiretroviral drugs increased the risks of preterm delivery and other adverse pregnancy outcomes[15,21]. Differences in the types of antiviral drugs, timing of ART initiation and maternal HIV disease stage prior to conception may have a stronger influence on the risk of preterm birth than the ART regimen type. In addition, the causes of preterm birth are multifactorial, and associated risk factors include the socioeconomic status, maternal body-mass index, maternal smoking, under-nutrition, environmental exposure and maternal infection.
Item Preterm birth Term birth P-value NNRTI-based cART 23 126 0.99 PI-based cART 34 186 mono/dual ART 15 75 No treatment 17 88
Table 6. Association of preterm birth with NNRTI-based cART, PI-based cART, Mono/dual ARTand no treatment
Few studies that investigated the effects of in utero exposure to ART and the occurrence of SGA births have yielded inconclusive results. Our study suggested that exposure to cART during pregnancy was associated with a higher risk of SGA when compared with no treatment. Erika Aaron found that women who received a non-nucleoside reverse-transciptase inhibitors-based regimen (NNRTI-based cART) were less likely to have a SGA neonate, compared to women receiving a PI-based regimen. However, after adjusting for socio-demographic factors, medication and HIV disease severity, no association of ART regimen type was associated with SGA. Still, one study conducted in Botswana found an association of SGA with cART during pregnancy. The ATHENA cohort suggested that the use of triple-drug ART, particularly a PI-based regimen, prior to conception was associated with SGA. Other studies reported no evidence of an association between ART during pregnancy and SGA at delivery[31,36,37].
A systematic review reported inconclusive findings regarding the effects of in utero HIV and ART exposure on postnatal weight gain in HIV-exposed infants. A smaller study conducted in China found no effect of maternal cART use during pregnancy on infant growth at 18 months of age, consistent with our findings. Still, other studies demonstrated that HIV-exposed infants exhibited poorer growth than their HIV-unexposed counterparts[40,41]. One study conducted in Botswana suggested that children exposed to cART in utero had significantly lower length-for-age and weight-for-age Z scores, compared to those exposed to zidovudine monotherapy. Another study conducted in South Africa found no association between the duration of Tenofovir exposure in utero and the early linear growth of infants. These inconsistent findings may be attributed to the use of different antiviral drugs by the mothers, the evaluation of infants in different age groups and differences in the feeding modes and nutritional statuses during early infancy.
Our study had several strengths, including the reported effects of in utero HIV and ART exposure on pregnancy outcomes and early infant growth at 4 weeks-age. Such research is rare in China, where a huge number of HIV-infected women have yet to receive ART in compliance with the implemented PMTCT. We comprehensively discussed the effects of three groups of mothers−those receiving no treatment, mono/dual ART or cART−to inform target populations and policy makers for advance the universal access.
However, our study also had some limitations. First, the study used an observational design, rather than a randomized controlled clinical trial design, to address whether the uses of different ART regimens would be associated with adverse pregnancy outcomes and adverse early infant growth. Some unmeasured confounders may have biased our results. We could not compare other outcomes such as the maternal viral load at the time of labor, maternal nutrition, maternal BMI and the induced or spontaneous status of preterm birth. However, several studies of pregnant HIV-infected women documented associations between poor nutrition, a low maternal BMI and advanced maternal HIV disease[43,44]. Second, few women with HIV underwent CD4 count analyses during the third trimester, as the new ART treatment guidelines do not require this test prior to ART initiation. However, this deficiency would randomly appear among the three groups. Third, growth information was not available for 175 of 562 newborns (31.1%), which may have biased the research results. Although 90% of infants received early HIV testing in recent years, the body length, weight and other indicators were not measured in many children because their guardians considered the physical growth of infants to be unimportant. Finally, this study focused only on the short-term effects of pregnancy outcomes and infant growth at 4 weeks’ postpartum and could not address the long-term effects of intrauterine exposure to ART.
In conclusion, the administration of ART to HIV-infected pregnant women will remain a global high-priority issue, as even mono/dual ART can improve pregnancy outcomes and infant survival in resource-limited countries. The reduction of serious adverse fetal and infant outcomes and the risk of MTCT are critical issues. Further studies are needed to monitor the short-and long-term health effects of HIV and ART exposure and thus optimize antiretroviral therapy during pregnancy.
Effects of Antiretroviral Therapy and HIV Exposure in Utero on Adverse Pregnancy and Infant Outcomes: A Prospective Cohort Study in Guangzhou, China
- Received Date: 2019-02-26
- Accepted Date: 2019-07-12
- HIV /
- Adverse pregnancy outcome /
- Adverse infant outcome /
- Mother-to-child transmission (MTCT) /
- Antiretroviral therapy (ART)
|Citation:||HU Fang, LIANG Jing Jing, LU Jian Jun, HU Yi Fei, HU Yan, YU Jia, ZOU Xing Wen, MA Ying Hua, LIN Sui Fang. Effects of Antiretroviral Therapy and HIV Exposure in Utero on Adverse Pregnancy and Infant Outcomes: A Prospective Cohort Study in Guangzhou, China[J]. Biomedical and Environmental Sciences, 2019, 32(10): 719-729. doi: 10.3967/bes2019.092|